FIBROGEN INC (FGEN) Fundamental Analysis & Valuation

NASDAQ:FGEN • US31572Q8814

Current stock price

9.71 USD
+0.69 (+7.65%)
At close:
9.75 USD
+0.04 (+0.41%)
After Hours:

This FGEN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. FGEN Profitability Analysis

1.1 Basic Checks

  • In the past year FGEN was profitable.
  • FGEN had a negative operating cash flow in the past year.
  • FGEN had negative earnings in each of the past 5 years.
  • In the past 5 years FGEN reported 4 times negative operating cash flow.
FGEN Yearly Net Income VS EBIT VS OCF VS FCFFGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 157.40%, FGEN belongs to the top of the industry, outperforming 99.62% of the companies in the same industry.
Industry RankSector Rank
ROA 157.4%
ROE N/A
ROIC N/A
ROA(3y)-45.81%
ROA(5y)-39.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FGEN Yearly ROA, ROE, ROICFGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

  • FGEN has a Profit Margin of 2598.87%. This is amongst the best in the industry. FGEN outperforms 99.43% of its industry peers.
  • FGEN's Gross Margin of 345.69% is amongst the best of the industry. FGEN outperforms 99.25% of its industry peers.
  • FGEN's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 2598.87%
GM 345.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.51%
GM growth 5Y-13.76%
FGEN Yearly Profit, Operating, Gross MarginsFGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. FGEN Health Analysis

2.1 Basic Checks

  • FGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • FGEN has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, FGEN has more shares outstanding
  • FGEN has a worse debt/assets ratio than last year.
FGEN Yearly Shares OutstandingFGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
FGEN Yearly Total Debt VS Total AssetsFGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • FGEN has an Altman-Z score of -19.17. This is a bad value and indicates that FGEN is not financially healthy and even has some risk of bankruptcy.
  • FGEN has a worse Altman-Z score (-19.17) than 81.51% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -19.17
ROIC/WACCN/A
WACC14.71%
FGEN Yearly LT Debt VS Equity VS FCFFGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • FGEN has a Current Ratio of 3.71. This indicates that FGEN is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.71, FGEN is in line with its industry, outperforming 45.09% of the companies in the same industry.
  • A Quick Ratio of 3.60 indicates that FGEN has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.60, FGEN is in line with its industry, outperforming 45.66% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.71
Quick Ratio 3.6
FGEN Yearly Current Assets VS Current LiabilitesFGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. FGEN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 102.02% over the past year.
  • FGEN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -95.39%.
  • The Revenue for FGEN have been decreasing by -35.07% on average. This is quite bad
EPS 1Y (TTM)102.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-49.88%
Revenue growth 5Y-35.07%
Sales Q2Q%-97.68%

3.2 Future

  • FGEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.11% yearly.
  • FGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.58% yearly.
EPS Next Y60.86%
EPS Next 2Y-0.78%
EPS Next 3Y3.05%
EPS Next 5Y15.11%
Revenue Next Year-96.2%
Revenue Next 2Y-81.45%
Revenue Next 3Y-67.47%
Revenue Next 5Y9.58%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FGEN Yearly Revenue VS EstimatesFGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
FGEN Yearly EPS VS EstimatesFGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

3

4. FGEN Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 15.66 indicates a correct valuation of FGEN.
  • Based on the Price/Earnings ratio, FGEN is valued cheaper than 95.66% of the companies in the same industry.
  • FGEN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.21.
  • FGEN is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 15.66
Fwd PE N/A
FGEN Price Earnings VS Forward Price EarningsFGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FGEN Per share dataFGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.26
PEG (5Y)N/A
EPS Next 2Y-0.78%
EPS Next 3Y3.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FGEN Dividend Analysis

5.1 Amount

  • No dividends for FGEN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FGEN Fundamentals: All Metrics, Ratios and Statistics

FIBROGEN INC

NASDAQ:FGEN (1/7/2026, 8:00:00 PM)

After market: 9.75 +0.04 (+0.41%)

9.71

+0.69 (+7.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-16
Inst OwnersN/A
Inst Owner Change5.17%
Ins OwnersN/A
Ins Owner Change0.03%
Market Cap39.33M
Revenue(TTM)8.30M
Net Income(TTM)215.65M
Analysts80
Price Target43.86 (351.7%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.24%
Min EPS beat(2)20.04%
Max EPS beat(2)20.44%
EPS beat(4)4
Avg EPS beat(4)102.91%
Min EPS beat(4)20.04%
Max EPS beat(4)226.05%
EPS beat(8)7
Avg EPS beat(8)62.43%
EPS beat(12)9
Avg EPS beat(12)43.37%
EPS beat(16)11
Avg EPS beat(16)26.6%
Revenue beat(2)0
Avg Revenue beat(2)-42.72%
Min Revenue beat(2)-49.76%
Max Revenue beat(2)-35.68%
Revenue beat(4)2
Avg Revenue beat(4)22.7%
Min Revenue beat(4)-49.76%
Max Revenue beat(4)98.39%
Revenue beat(8)5
Avg Revenue beat(8)22.82%
Revenue beat(12)9
Avg Revenue beat(12)22.18%
Revenue beat(16)10
Avg Revenue beat(16)15.07%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)10.69%
EPS NQ rev (3m)6.83%
EPS NY rev (1m)17.62%
EPS NY rev (3m)17.62%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.29%
Revenue NY rev (1m)0.75%
Revenue NY rev (3m)0.75%
Valuation
Industry RankSector Rank
PE 15.66
Fwd PE N/A
P/S 4.74
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.62
EY6.39%
EPS(NY)-12.19
Fwd EYN/A
FCF(TTM)-4.22
FCFYN/A
OCF(TTM)-4.18
OCFYN/A
SpS2.05
BVpS-4.2
TBVpS-4.2
PEG (NY)0.26
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 157.4%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 2598.87%
GM 345.69%
FCFM N/A
ROA(3y)-45.81%
ROA(5y)-39.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.51%
GM growth 5Y-13.76%
F-Score5
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.39%
Cap/Sales 2.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.71
Quick Ratio 3.6
Altman-Z -19.17
F-Score5
WACC14.71%
ROIC/WACCN/A
Cap/Depr(3y)133.57%
Cap/Depr(5y)124.53%
Cap/Sales(3y)11.27%
Cap/Sales(5y)9.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)102.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
EPS Next Y60.86%
EPS Next 2Y-0.78%
EPS Next 3Y3.05%
EPS Next 5Y15.11%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-49.88%
Revenue growth 5Y-35.07%
Sales Q2Q%-97.68%
Revenue Next Year-96.2%
Revenue Next 2Y-81.45%
Revenue Next 3Y-67.47%
Revenue Next 5Y9.58%
EBIT growth 1Y-29.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.53%
EBIT Next 3Y7.86%
EBIT Next 5Y4.1%
FCF growth 1Y95.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y95.16%
OCF growth 3YN/A
OCF growth 5YN/A

FIBROGEN INC / FGEN Fundamental Analysis FAQ

What is the ChartMill fundamental rating of FIBROGEN INC (FGEN) stock?

ChartMill assigns a fundamental rating of 3 / 10 to FGEN.


What is the valuation status of FIBROGEN INC (FGEN) stock?

ChartMill assigns a valuation rating of 3 / 10 to FIBROGEN INC (FGEN). This can be considered as Overvalued.


How profitable is FIBROGEN INC (FGEN) stock?

FIBROGEN INC (FGEN) has a profitability rating of 3 / 10.


What is the valuation of FIBROGEN INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for FIBROGEN INC (FGEN) is 15.66 and the Price/Book (PB) ratio is -2.31.


What is the expected EPS growth for FIBROGEN INC (FGEN) stock?

The Earnings per Share (EPS) of FIBROGEN INC (FGEN) is expected to grow by 60.86% in the next year.